Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSONANCE Extension: Ocrelizumab in Progressive MS
NCT05210621Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2022
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Proportion of patients with upper limb disability progression at Week 192. Started Mar 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05210621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210621.